<!doctype html>
<html lang="en">

<head>
    <meta charset="utf-8">
    </meta>
    <title>Jon Akutagawa</title>
    <!--<link href='https://fonts.googleapis.com/css?family=Droid+Sans' rel='stylesheet' type='text/css'>-->
    <link rel="stylesheet" type="text/css" href=style.css />
</head>

<body>
    <section>
        <!--<nav>
            <h1><a href="https://jakutagawa.github.io">Jon Akutagawa</a></h1>
            <ul>
                <li><a href="about.html">About</a></li>
                <li><a href="publications.html">Publications</a></li>
            </ul>
        </nav>-->
        <table summary="Table for page layout." id="tlayout">
            <tr valign="top">
                <td id="layout-menu">
                    <div class="menu-item"><a href="https://jakutagawa.github.io">Home</a></div>
                    <div class="menu-item"><a href="publications.html" class="current">Publications</a></div>
                    <div class="menu-item"><a href="about.html">About</a></div>
                </td>

                <article>
                    <td id="layout-content">
                        <h1><a href="https://jakutagawa.github.io" class="nounderline">Jon Akutagawa</a></h1>
                        <p>
                            <li>Tran TH, Nguyen JV, Stecula A, <strong>Akutagawa J</strong>, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. 
                                "The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment.” <i>Haematologica</i>. 2021 Aug 1;106(8):2242-2245.<br></li><br>
                            <li>Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, <strong>Akutagawa J</strong>, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML. “Bcl-2 Is a Therapeutic Target for Hypodiploid
                                B-Lineage Acute Lymphoblastic Leukemia.” <i>Cancer Res</i>. 2019 May 1;79(9):2339-2351.<br></li><br>
                            <li>Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, <strong>Akutagawa J</strong>, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML. (2017). Genome-wide DNA methylation is predictive of outcome in
                                juvenile myelomonocytic leukemia. <i>Nature Communications</i>, 8, 2127.<br></li><br>
                            <li><strong>Akutagawa J*</strong>, Huang TQ*, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS. (2016). Targeting the PI3K/Akt pathway in murine MDS/MPN driven by
                                hyperactive Ras. <i>Leukemia</i>, 30(February), 1–9.<br></li><br>
                            <li>Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, <strong>Akutagawa J</strong>, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML. (2015).
                                Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i>, 125(3), 516–524.</li><br>
                            <li>Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, <strong>Akutagawa J</strong>, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. (2013). PLC-γ and PI3K
                                link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. <i>Science Signaling</i>, 6(304), ra105.</li><br>
                            <li>Chang T, Krisman K, Theobald EH, Xu J, <strong>Akutagawa J</strong>, Lauchle JO, Kogan S, Braun BS, Shannon K. (2013). Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. <i>Journal of
                                    Clinical Investigation</i>, 123(1), 335–339.</li><br>
                            <li>Lyubynska N, Gorman MF, Lauchle JO, Hong WX, <strong>Akutagawa JK</strong>, Shannon K, Braun BS. (2011). A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. <i>Sci Transl Med</i>, 3(76), 76ra27.
                            </li><br>
                            <li>Stephan JP, Chan P, Lee C, Nelson C, Elliott J M, Bechtel C, Raab H, Xie D, <strong>Akutagawa J</strong>, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A. (2008). Anti-CD22-MCC-DM1 and MC-MMAF
                                conjugates: Impact of assay format on pharmacokinetic parameters determination. <i>Bioconjugate Chemistry</i>, 19(8), 1673–1683.</li>
                        </p>
                        <a href="#top">[top]</a><br>
                        <footer>
                            &copy; 2022 by Jon Akutagawa.
                        </footer>
                    </td>
            </tr>
            </article>
        </table>
    </section>
</body>

</html>
